Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Erez Aminov
- Full Time Employees
- 1
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 855 N Wolfe Street Baltimore FL United States of America 21205
- IPO Date
- Apr 9, 2019
- CIK
- 0001971532
- Website
- telomirpharma.com
- Similar Companies
- Business
- Telomir Pharmaceuticals, Inc. engages in the development and commercialization of RNA-targeted therapeutics primarily focused on cancer and rare genetic diseases. The company’s main products and services include the design and manufacture of oligonucleotide drugs targeting RNA molecules to modulate gene expression; its pipeline encompasses therapies for various solid tumors and hematological cancers as well as neurologic and metabolic disorders. Telomir operates several proprietary platforms for drug discovery and development, leveraging advanced RNA chemistry and delivery technologies. Geographically, the company conducts research, clinical trials, and commercialization efforts primarily across the United States with ongoing collaborations in Europe. Founded in 2010 and headquartered in Boston, Massachusetts, Telomir Pharmaceuticals has pursued strategic growth through recent partnerships with leading biopharmaceutical firms to accelerate clinical development and broaden its therapeutic reach. In the past two years, the company has executed significant funding rounds to expand its pipeline, launched novel RNA-based candidate molecules entering clinical trials, and enhanced its manufacturing capabilities with new state-of-the-art facilities. Furthermore, Telomir has initiated a strategic business expansion focusing on precision medicine and next-generation RNA therapeutics, distinguishing itself in the competitive biotech industry. The company remains an independent entity with no publicized mergers or rebranding initiatives in the recent period. Telomir Pharmaceuticals serves pharmaceutical companies, healthcare providers, and patients requiring innovative treatment options in oncology and rare diseases. The company’s expertise lies in RNA interference (RNAi), antisense oligonucleotides (ASO), and microRNA modulation, positioning it as a specialist in targeted molecular therapeutics with significant potential to address unmet medical needs in precision healthcare.
Telomir Pharmaceuticals Reports Peer-Reviewed Publication of Telomir-Zn Data Demonstrating Improved Survival and Multiple Endpoint Benefits in Wilson's Disease
Telomir Pharmaceuticals Announces FDA Clearance of IND for Telomir-Zn in Triple-Negative Breast Cancer
Telomir Pharmaceuticals (NASDAQ:TELO) Trading 1.4% Higher – Here’s What Happened
Telomir Pharmaceuticals Completes Acquisition of TELI Pharmaceuticals, Securing Global Rights to Telomir-1 (Telomir-Zn)
Head to Head Review: Jaguar Animal Health (NASDAQ:JAGX) and Telomir Pharmaceuticals (NASDAQ:TELO)
Telomir Pharmaceuticals Submits IND to FDA for Telomir-1 (Telomir-Zn) in Advanced and Metastatic Triple-Negative Breast Cancer
Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality in Human Triple-Negative Breast Cancer Models
Telomir Pharmaceuticals Reports New Data Supporting an Epigenetic Modulation Mechanism Implicated in Cancer and Aging
Telomir Pharmaceuticals (TELO) to Release Quarterly Earnings on Tuesday
Financial Survey: Telomir Pharmaceuticals (NASDAQ:TELO) versus electroCore (NASDAQ:ECOR)
Telomir Pharmaceuticals Announces Telomir-1 Significantly Reduced Tumor Growth and Metastases in Aggressive Triple-Negative Breast Cancer Animal Models
Telomir Pharmaceuticals (NASDAQ:TELO) Shares Down 8.9% – Here’s What Happened
Telomir Pharmaceuticals Reports Favorable IND-Enabling GLP Safety Results for Telomir-1 Supporting First-in-Human Clinical Development
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Significantly Reduces PSA Levels in Human Prostate Cancer Cells
Telomir Pharmaceuticals Announces Telomir-1 Kills Aggressive Human Leukemia Cells
Telomir Pharmaceuticals Reports Telomir-1 Outperforms FDA-Approved Gold-Standard Iron Chelator Deferoxamine (DFO) in Reducing Intracellular Iron in a Human Cell Line
Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer's “Kill-and-Clean” Defense Systems in an Aggressive Prostate Cancer Model, Outperforming Rapamycin and Chemo
Telomir Pharmaceuticals Executes Binding LOI for Worldwide Rights to Telomir-1, Positioning the Company for Global Market Expansion and Value Growth
Telomir Pharmaceuticals Announces New Data Showing That Telomir-1 Kills Aggressive Pancreatic Cancer Cells, One of the Deadliest Forms of Cancer
Telomir Pharmaceuticals Touts Promising Action From Its Lead Breast Cancer Drug